[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transcranial-electric-stimulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transcranial-electric-stimulation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100650847","mechanistic-validation-of-human-multipolar-tes-ti-amplitude-modulation-frequency-and-benchmarking-100650847",false,"NCT07752745","Mechanistic Validation of Human Multipolar TES-TI: Amplitude Modulation, Frequency, and Benchmarking","MINT","Inclusion Criteria:\n\n* Medically healthy (based on self-report and study team review)\n* U.S. citizen or holding permanent resident status\n* English-speaking (able to provide consent and complete questionnaires)\n\nExclusion Criteria:\n\n* Current or past history of clinically significant neurological disorder or acquired neurological disease (e.g., stroke, traumatic brain injury), including intracranial lesions (including clinically significant findings identified on the structural MRI)\n* History of inpatient psychiatric hospitalization\n* History of head trauma resulting in prolonged loss of consciousness; or a history of \\>3 grade I concussions\n* Current poorly controlled headaches, including intractable or frequent migraines\n* Any systemic illness or unstable medical condition that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)\n* History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG, or family history of treatment resistant epilepsy except for a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist\n* Possible pregnancy or plan to become pregnant in the next 6 months (self reported)\n* Any metal in the head\n* Any medical devices or implants (i.e. cardiac pacemaker, medication infusion pump, cochlear implant, vagal nerve stimulator)\n* Dental implants\n* Permanent retainers\n* Any hair braid, dreadlocks, hair pieces, or extensions which cannot be taken out before the study sessions\n* Any head coverings or headdress that participant feels uncomfortable removing for the purposes of study sessions\n* Current use of medications known to substantially lower seizure threshold, specifically chlorpromazine, clozapine, bupropion, clomipramine, or maprotiline; or other medications at doses known to substantially lower seizure threshold in the judgment of the PI\n* Active scalp lesions, broken skin, or skin conditions at planned electrode sites that would preclude safe electrode application\n* Claustrophobia (a fear of small or closed places)\n* Back problems that would prevent lying flat for up to two hours",true,"ALL","18 Years","50 Years",{"count":21,"type":22},24,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is to find out whether and how a type of non-invasive electrical brain stimulation called transcranial electrical stimulation with temporal interference (TES-TI) can temporarily change brain activity in healthy adults. A structural MRI scan will be used to customize where the stimulation electrodes are placed for each participant to deliver TES-TI during three afternoon sessions at rest with eyes closed. Brain activity is recorded with high-density EEG. Up to 24 participants will be enrolled and on study for 3 to 12 weeks.",[28],"Transcranial Electric Stimulation","NOT_YET_RECRUITING","2026-08-03",{"date":32,"type":33},"2026-08-07","ACTUAL",{"date":35,"type":22},"2026-09",{"date":37,"type":22},"2028-02",{"name":39,"class":40},"University of Wisconsin, Madison","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100592310","investigating-the-effectiveness-of-a-2-week-novel-non-invasive-brain-stimulation-technique-on-cognitive-outcomes-in-healthy-adults-100592310","NCT06991764","Investigating the Effectiveness of a 2-week Novel Non-invasive Brain Stimulation Technique on Cognitive Outcomes in Healthy Adults","Investigating the Effectiveness of a 2-week High-frequency Transcranial Pulsed-current Stimulation on Cognitive Outcomes in Healthy Adults: A Randomised, Double Blinded, Sham-controlled Study","Inclusion Criteria:\n\n* Male and female young (21 to 30 years) and older adults (60 to 75 years)\n* Right-handed\n* Must be a native English speaker\n* No clinical diagnosis of neurodevelopmental, mood, neurological or neurodegenerative disorders\n* Adults with cardiometabolic or cardiovascular conditions may participate if their condition is controlled and stable with medication and \u002F or lifestyle interventions\n\nExclusion Criteria:\n\n* Currently on long-term medication for pain or migraines \u002F headaches\n* Adults with metallic implants in the chest or head region\n* Adults with epilepsy, or known seizure or immediate family members that have had a seizure before\n* Had a recent head injury that resulted in a temporary loss of consciousness or of memory in the last 12 months\n* Had prior head surgery\n* Prone to fainting\n* Sensitive skin or prone to skin allergies","21 Years","75 Years",{"count":52,"type":22},120,[25],"The goal of this randomised controlled trial is to investigate the effects of a 2-week high-frequency transcranial pulsed current stimulation (tPCS) on cognitive outcomes in older and healthy adults. The main questions it aims to answer are:\n\n1. Would a single session of anodal tPCS over the left prefrontal cortex improve working memory, task inhibition, and task switching in healthy young and older adults, compared to anodal transcranial direct current stimulation (tDCS) and sham-tPCS?\n2. Would repeated session of anodal-tPCS (2-weeks) lead to improvements in working memory, task inhibition, and task switching in healthy young and older adults, compared to tDCS and sham-tPCS?\n3. Will tPCS be better tolerated among healthy adults, compared to tDCS?\n\nResearchers will compare tPCS \u002F tDCS \u002F sham-tPCS to see if there are any differences in cognitive outcomes after 1 session and after repeated sessions, as well as to compare the tolerance of tPCS against tDCS and sham-tPCS.\n\nParticipants will be requested to:\n\n* Undergo 1 of 3 of the following conditions: tDCS \u002F tPCS \u002F sham-tPCS\n* Complete three sessions of cognitive tasks testing working memory, inhibition and task switching at baseline (pre-stimulation), after day 1 of brain stimulation and after 10 sessions of brain stimulation (post- repeated stimulation)\n* Undergo fNIRS-EEG brain measurements concurrently with the cognitive tasks",[56,57,58,28],"Transcranial Direct Current Stimulation (tDCS)","Ageing","Executive Functioning",[60,61,58,62,63,64,57],"Randomised Controlled Trial","Non-Invasive Brain Stimulation","Transcranial Direct Current Stimulation","Transcranial Pulsed Current Stimulation","Healthy Adults","2025-05-18",{"date":67,"type":33},"2025-05-28",{"date":69,"type":22},"2025-06-01",{"date":71,"type":22},"2027-04-30",{"name":73,"class":40},"Nanyang Technological University",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":18,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":92,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":41},"100532423","optimized-and-personalized-trans-cranial-brain-stimulation-in-partial-refractory-epilepsies-100532423","NCT06212609","Optimized and Personalized Trans-cranial Brain Stimulation in Partial Refractory Epilepsies","PerEpi2","Inclusion Criteria:\n\n* Any patient, male or female aged 1 to 18, with refractory partial epilepsy considered potentially surgical according to the definition of ILAE. Drug-resistant epilepsy can be defined as the failure of adequate therapeutic trials of two antiepileptics (either monotherapy or in combination) so that the patient is free from seizures on a lasting basis.\n* Any epileptic patient with interictal epileptic spikes on his standard or High Resolution EEG and or on the Magnetoencephalography examination\n* Any epileptic patient undergoing a structural MRI\n* Any patient who has agreed to participate in the PerEpi 1 study allowing the optimization of the location of epileptic sources and the modelling of the optimization of the parameters of transcranial electrical stimulation\n* Patients who have at least 4 seizures per month\n\nExclusion Criteria:\n\n* Patient not meeting the age criteria\n* And\u002For presenting generalized epilepsy\n* And\u002For presenting diffuse interictal peaks and\u002For presenting a serious alteration of the general condition and vital functions\n* And\u002For in the event of refusal by one of the parents or the child\n* Pregnant, parturient or breastfeeding woman.\n* Contraindication to the use of mc-tDCS stimulation without seizure","1 Year",{"count":83,"type":22},20,[25],"Epilepsy is one of the most common neurological diseases, affecting between 0.5% and 1% of the general population. Therefore, new diagnostic and treatment methods are having a big impact on society. Epilepsy is also one of the most commonly diagnosed pediatric neurological disorders, with long-term implications for the quality of life of those affected and their relatives. In only two-thirds of cases, seizures can be adequately controlled with anticonvulsant drug therapy. For other patients with a drug-resistant focal epilepsy (up to around 2 million in Europe) epilepsy surgery is currently the most effective treatment. However, only 15-20% of these drug-resistant patients are eligible for epilepsy surgery. This is either because the cortical epileptogenic zone cannot be localized with sufficient precision with standard diagnostic means, or because the epileptogenic zone overlaps meaningful cortical areas, so that it cannot be surgically removed without considerable neurological deficit.",[28,87,88,89,90,91],"tDCS","Epilepsy","Pharmacoresistant","HR EEG","Children",[93,87,88,94,90,95],"Transcranial electric stimulation","pharmacoresistant","children","RECRUITING","2024-01-30",{"date":99,"type":33},"2024-01-31",{"date":101,"type":33},"2023-12-01",{"date":103,"type":22},"2027-01-01",{"name":105,"class":40},"Centre Hospitalier Universitaire, Amiens"]